Today, VeriSIM Life (VeriSIM) announces the launch of its pharmaceutical subsidiary, PulmoSIM Therapeutics (PulmoSIM) with the mission to address the unmet needs in the treatment of rare respiratory diseases, with an immediate emphasis on pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF).
PulmoSIM is developing breakthrough therapies for rare and progressive respiratory diseases to improve patient outcomes and quality of life. PulmoSIM’s approach modulates multiple biological pathways with a single agent, thus alleviating the need of combination therapies. With repurposing and repositioning already approved FDA drugs, PulmoSIM is targeting the underlying biology to effectively treat PAH and IPF.
“We are thrilled to announce the launch of PulmoSIM as it demonstrates the indefinite capabilities of the VeriSIM’s platform, BIOiSIM, in accelerating drug development by bridging the translational gap between preclinical and clinical phases. In contrast to working with pharmaceutical and biotech companies in developing their drug portfolios, the PulmoSIM launch will be the first of many assets we will be developing to solve the most challenging and unaddressed diseases impacting human-kind”, said Dr. Jo Varshney.
“Out of >7,000 rare diseases, many exist in hard-to-reach peripheral regions of the respiratory system. PulmoSIM aims to leverage the immense potential drug repurposing has to offer, to tackle at least a few of these rare diseases. Development of affordable, and commercially feasible therapies is one of the many ways to improve quality of life and compliance among the patients suffering from these indications”, said the Scientific Founder, Dr. Vivek Gupta.
PulmoSIM is also pleased to announce the establishment of its Scientific Advisory Board: Dr. Eva S. Nozik, MD (Professor, Pediatrics-Critical Care Medicine, School of Medicine, University of Colorado, Denver, CO), Dr. Samir Mitragotri, PhD (Hiller Professor of Bioengineering and Wyss Professor of Biologically Inspired Engineering, Harvard University, Boston, MA), and Dr. Hugh Smyth, PhD (Alcon Centennial Professor of Molecular Pharmaceutics and Drug Delivery, University of Texas, Austin, TX).
“Unlike current approaches that seek symptomatic relief, PulmoSIM’s approach is novel as it targets the biology of the disease. Targeting the underlying disease mechanisms opens the path to effective and life-saving therapies”, said Dr. Samir Mitragotri.
The launch of PulmoSIM is an exciting venture for VeriSIM, and is the next phase in leveraging their first-in-class artificial intelligence platform to predict the clinical efficacy of drugs and propel drug development innovation forward. The PulmoSIM team is well-versed in respiratory diseases, product development, and has the experience, expertise, and relationships to efficiently address further operational, clinical, regulatory, competitive, and financial risks as we propel to clinical proof-of-concept. To learn more about our pipeline, approach, and how we can partner – contact us at: email@example.com